Who are we

Cambridge Vision Technology (CVT) is an integrated medical device company focused on delivering scientifically validated diagnostic tests & biomarkers for early detection and monitoring of ophthalmic, and neurodegenerative diseases.

Our focus

There is a significant unmet need for cost-effective, noninvasive, and scalable Alzheimer’s Disease (AD) risk screening biomarkers, that are capable of detecting AD in the earliest pathologic stages (preclinical AD), before clinical symptoms are evident. CVT targets biomarkers in the human retina, an extension of the central nervous system (CNS) that can be visualized non-invasively using standard ophthalmologic techniques.


Alzheimer’s disease biomarker measurements

Our first product, A-Eye Scope, is an integrated hardware, software platform that identifies characteristic of Mild Cognitive Impairment (MCI) and Alzheimer’s disease pathology in the retina. Our automated hardware captures an image of the patient’s retina. Our machine learning algorithms combine information from the extracted vascular biomarkers with non-imaging inputs such as gender, and cognitive test scores in order to stratify the patients on the Alzheimer’s disease continuum.